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The cancer-testis antigen NY-ESO-1 has been used as a target for different immunotherapies like vaccinations and adoptive
transfer of antigen-specific cytotoxic T cells, as it is expressed in various tumor types and has limited expression in normal
cells. The in vitro generation of T cells with defined antigen specificity by T cell receptor (TCR) gene transfer is an established
method to create cells for immunotherapy. However, an extensive characterization of TCR which are candidates for treatment
of patients is crucial for successful therapies. The TCR has to be efficiently expressed, their affinity to the desired antigen
should be high enough to recognize low amounts of endogenously processed peptides on tumor cells, and the TCR should not
be cross-reactive to other antigens. We characterized three NY-ESO-1 antigen-reactive cytotoxic T lymphocyte clones which
were generated by different approaches of T cell priming (autologous, allogeneic), and transferred their TCR into donor T cells
for more extensive evaluations. Although one TCR most efficiently bound MHC-multimers loaded with NY-ESO-1 peptide, T
cells expressing this transgenic TCR were not able to recognize endogenously processed antigen. A second TCR recognized
HLA-A2 independent of the bound peptide beside its much stronger recognition of NY-ESO-1 bound to HLA-A2. A third TCR
displayed an intermediate but peptide-specific performance in all functional assays and, therefore, is the most promising
candidate TCR for further clinical development. Our data indicate that multiple parameters of TCR gene-modified T cells have
to be evaluated to identify an optimal TCR candidate for adoptive therapy.
The cancer-testis antigen NY-ESO-1 is an attractive target for
specific immunotherapies, as it is expressed in many different
solid tumors and hematological malignancies.1 In addition,
the expression in normal tissue seems to be mainly restricted
to immune privileged germ cells. NY-ESO-1 was originally
identified by serological analysis of recombinant cDNA
expression libraries using tumor mRNA and autologous se-
rum from a patient with esophageal squamous cell carci-
noma,2 indicating that a humoral immune response can
spontaneously arise in tumor patients. Moreover, NY-ESO-1
epitopes for CD4þ and CD8þ T cells were identified and
these T cells were found in many patients with NY-ESO-1þ
tumors.3,4 Due to the proven immunogenicity of NY-ESO-1
several vaccination studies were performed. Although an
increase in NY-ESO-1-specific T cells was observed in vacci-
nated patients, the clinical benefit was limited.5 One reason
for the poor reactivity of T cells after vaccination might be
the absence of high avidity T cells as these cells are probably
deleted in the thymus due to NY-ESO-1 expression in med-
ullary thymic epithelial cells.6 A possibility to circumvent this
problem is the adoptive transfer of high avidity NY-ESO-1-
specific T cells into patients. To reproducibly generate these
T cells for every patient, autologous T cells can be modified
with genes encoding for high affinity T cell receptors (TCRs).
In a recent clinical study using this approach, nine of 17
patients showed clinical responses without serious side
effects,7 confirming that NY-ESO-1 is a suitable antigen for
adoptive T cell therapies. For a successful therapy with TCR
gene-modified T cells it is crucial to use TCR with
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sufficiently high affinities toward their antigen. TCR genes
can be isolated from tumor infiltrating lymphocytes, which
have the advantage that they have been primed in vivo. How-
ever, often low avidity T cells have been isolated, because
tumor-associated antigens, such as NY-ESO-1 are also
expressed by normal tissues including the thymus. A second
source for TCR is T cells which were generated by ‘‘reverse
immunology.’’ For this approach, an antigen is chosen and
then peripheral blood lymphocytes (PBL) from a—in most
cases healthy—donor are stimulated with this antigen to
induce proliferation of T cells with the desired specificity.
These cells can then be enriched and cloned by limiting dilu-
tion.8 To induce high avidity T cells against self antigens, PBL
from allogeneic donors can be used.9 In this case an HLA mis-
match between the T cells and the antigen presenting cells
allows the isolation of unselected T cells. However, this
approach bears the risk that the antigen recognition of the iso-
lated TCR is dominated by the binding to the foreign major
histocompatibility complex (MHC) molecule.10 So far, only
NY-ESO-1-specific TCR-transgenic (TCR-tg) T cells with TCR
originating from autologous approaches have been
described.11,12 In this study, we have characterized three differ-
ent NY-ESO-1-specific TCR, which were isolated from T cell
clones generated by autologous and allogeneic approaches in
order to evaluate them for their potential therapeutical usage.
Material and Methods
Cells
Cell lines 293T (ATCC: CRL-11268, American Type Culture
Collection, Manassas, VA), SK-Mel-29,13 SK-Mel-37,13
Mel-285 (B. Ksander, Schepens Eye Institute, Boston, MA),
Me-32414 and MUC-Mel-115 were cultured in Dulbecco’s
modified Eagle’s medium (GIBCO, Karlsruhe, Germany) sup-
plemented with 10% fetal calf serum (Biochrom AG, Berlin,
Germany) and 100 U/ml penicillin/streptomycin. The renal
cell carcinoma cell lines KT-195-VC and KT-195-A216 were
cultured in RPMI 1640 medium (GIBCO) supplemented with
10% fetal calf serum, 1 mM sodium pyruvate (GIBCO), and
100 U/ml penicillin/streptomycin. NY-ESO-1-expressing SK-
Mel-29 cells (SK-Mel-29-NY) were generated by transducing
them with the retroviral vector MIG containing the NY-ESO-1
gene. In parallel, cells were transduced with an empty MIG
vector (SK-Mel-29-VC). Both cell populations were enriched
for transduced cells by fluorescence activated cell sorting
(FACS) based on green fluorescence protein (GFP) expression.
PBL were isolated from blood of healthy donors with
donors’ informed consent by ficoll gradient centrifugation
and seeded in a concentration of 1  106 per well and ml in
the presence of 100 U/ml interleukin-2 (kindly provided by
Chiron, Marburg, Germany) in non-tissue culture 24-well
plates, precoated with anti-CD3 (5 lg/ml) and anti-CD28 (1
lg/ml) monoclonal antibodies (mAb) (BD Pharmingen, Hei-
delberg, Germany) for stimulation. On day 13 after isolation,
PBL were rested for two days by reducing the interleukin-2
concentration to 10 U/ml. Human PBL, Jurkat76/CD8 (J76/
CD8) and T2 (ATCC: CRL-1992) cells were cultured in
RPMI 1640 medium supplemented with 10% fetal calf serum
(PAN Biotech, Aidenbach, Germany), 1 mM HEPES and 100
U/ml penicillin/streptomycin. All cell culture flasks and plates
were purchased from BD Falcon (Franklin Lakes, NJ).
Generation of NY-ESO-1-specific T lymphocytes
The study was done in accordance with the precepts estab-
lished by the Helsinki Declaration and approved by the
Ethics Committee of the Technical University of Munich,
Germany. The generation of NY-ESO-1-specific cytotoxic T
lymphocyte (CTL) clones ThP2 and CM26 was described
previously.17 For generation of CTL clone HL-2, monocyte-
derived dendritic cells (DC) of an HLA-A2þ donor were
loaded with 5 lg/ml NY-ESO-1157-165-peptide (NY-ESO-1157-
165) and used for stimulation of autologous CD8
þ T cells.
Following two restimulations, HLA-A2/NY-ESO-1157-165-mul-
timerþ (NY-multimerþ) CD8þ T cells were sorted using a
Moflo cell sorter (Cytomation, Fort Collins, CO). Subse-
quently, sorted T cells were cloned by limiting dilution.18
Two weeks later, clones were screened in a chromium release
assay and NY-ESO-1-reactive clones were expanded as
described.19
Construction of retroviral vectors
To identify the sequences of the TCR genes, a 50-RACE-PCR
(GeneRacer Kit, Invitrogen, Karlsruhe, Germany) amplifying
the variable regions of the TCRa- and TCRb-chains includ-
ing CDR3 was performed with RNA isolated from the T cell
clones (Rneasy Mini Kit, Qiagen, Hilden, Germany). RACE-
PCR products were sequenced. The sequence of both TCR
constant regions were exchanged by minimally murinized
variants20 and mutated to create an additional disulfide
bond.21,22 TCRa- and TCRb-chains were linked by a 2A pep-
tide linker (TCRb-P2A-TCRa)23 and the complete constructs
What’s new?
The cancer-testis antigen NY-ESO-1 is expressed on many solid and hematological cancers but rarely in normal tissues and if
so, in immune-privileged germ cells. To test its therapeutic potential as a target for immunotherapies, the authors
characterized three different NY-ESO-1-specific T cell receptors, which were isolated from T cell clones generated by
autologous and allogeneic approaches. They find considerable differences in TCR behavior towards MHC-associated NY-ESO-1
peptides, underscoring that multiple functional parameters of TCR-transgenic T cells have to be thoroughly characterized prior
to clinical application of NY-ESO-1 directed immunotherapies.
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were codon-optimized24 and synthesized (GENEART,
Regensburg, Germany). The synthesized fragments were
cloned into the retroviral vector plasmid pMP71 via NotI
and EcoRI restriction sites.25
The NY-ESO-1 gene was amplified by PCR (50-primer:
TTTAGATCTGCCACCATGCAGGCCGAAGGCCG, 30-primer:
AAGAATTCATTAGCGCCTCTGCCCTGAGGG and cloned
into the retroviral vector plasmid pMIG26 via BglII and EcoRI
restriction sites.
Generation of retroviruses and transduction
Amphotropic MLV-10A1-pseudotyped retroviruses were pro-
duced as described.20 Forty-eight hours after transfection,
viral supernatants were filtrated (0.45 lm pore size) and used
directly for transduction. J76/CD8 cells (2  105 per well) were
incubated in 24-well non-tissue culture plates precoated with
RetroNectin (3.5 lg/well) (Takara, Apen, Germany) with 1 ml
retrovirus supernatant supplemented with protamine sulfate
(final concentration 4 lg/ml) (Sigma-Aldrich, Munich, Ger-
many). After addition of supernatant, plates were spinoculated
with 800g for 1.5 hr at 32C. PBL were transduced on day two
and three after isolation as described.23 The adherent cell line
SK-Mel-29 was seeded into 24-well-tissue culture plates one
day before transduction (5  104 cells per well). For transduc-
tion, 1 ml retrovirus supernatant supplemented with protamine
sulfate (final concentration 4 lg/ml) was added.
Flow cytometry
Cells were stained using fluorescein-isothiocyanate (FITC)-la-
beled mAb directed against human CD8 (BD Pharmingen),
phycoerythrine (PE)-labeled mAb directed against human
CD3 (BD Pharmingen) and allophycocyanin (APC)- or PE-
labeled NY-multimers (Coulter, Krefeld, Germany and Dirk
Busch, TU Munich, Germany, respectively). Fluorescence in-
tensity was measured using a FACSCalibur flow cytometer
(BD) and Cellquest Pro software (BD). Data were analyzed
using FlowJo software (Tree Star, Ashland, OR).
Cytokine release assay
TCR-tg PBL (1  105 per well) were co-cultured with 5 
104 target cells in 200 ll medium. PBL cultured without tar-
get cells and PBL stimulated with phorbol 12-myristate 13-
acetate (PMA)/ionomycin were used as negative and positive
controls, respectively. Peptides were synthesized by Metabion
(Martinsried, Germany) and loaded on T2 cells in a concen-
tration of 10 lM. Supernatants from co-cultured cells were
obtained after 24 hr and analyzed for content of human
interferon-c (IFN-c) by ELISA (BD Biosciences, Heidelberg,
Germany). IFN-c concentrations are given as mean values of
duplicates with mean deviation.
Cytotoxicity assay
Cytolytic activity of CTL clones and TCR-tg PBL against dif-
ferent target cell lines was determined in 4 hr chromium
release assays as described previously.15 To determine the
functional avidity, T cells were incubated with 1  103 for
CTL clones or 2  103 for TCR-tg PBL NY-ESO-1157-165-
loaded (1012 to 106 M) T2 cells. Specific and relative lysis
was calculated from duplicates at each E/T or peptide con-
centration as described.8
Results
Auto- and allo-HLA-A2-restricted CTL clones recognize the
same NY-ESO-1-derived epitope but differ in their multimer
binding and functionality
We generated NY-ESO-1-specific CTL clones by two differ-
ent strategies: DC from an HLA-A2þ donor were loaded
with NY-ESO-1157-165 and used for stimulation of autologous
and HLA-A2 allogeneic T cells, respectively. The autologous
approach was performed with cells from two different donors
and peptide concentrations of 200 lg/ml and 5 lg/ml. CTL
clones from all three different approaches were analyzed for
NY-ESO-1157-165 recognition and specific lysis of NY-ESO-1
þ
tumor cell lines (data not shown). From each approach the
clone with best function based on killing of tumor cell lines
was chosen: CM26 for the allogeneic approach, ThP2 for the
autologous approach with 200 lg/ml peptide and HL2 for
the autologous approach with 5 lg/ml peptide. All three
clones were CD8þ and bound NY-multimers (Fig. 1a). More-
over, NY-ESO-1157-165-loaded T2 cells were lysed by all three
clones, with the highest peptide sensitivity for the allo-HLA-
A2-restricted clone CM26 (Fig. 1b). T2 cells loaded with con-
trol peptides were not lysed (data not shown). Also endoge-
nously processed antigen recognized as HLA-A2þ/NY-ESO-
1þ tumor cell lines (SK-Mel-37 and SK-Mel-29-NY) were
lysed. In the experiment shown in Figure 1c, the CTL clone
CM26 displayed a relatively poor tumor cells lysis, which is
not representative for this CTL clone and might be due to
poor T cell fitness in this particular experiment. There was
no killing of HLA-A2þ/NY-ESO-1 tumor cell lines (SK-
Mel-29-VC) (Fig. 1c) or HLA-A2/NY-ESO-1þ tumor cell
lines (data not shown).
Functionality and MHC-multimer binding of NY-ESO-1 TCR
do not correlate
To further characterize the TCR expressed by the three CTL
clones ThP2, HL2 and CM26, we isolated the TCRa and
TCRb genes and cloned them into the retroviral vector
MP71 as optimized variants linked by a viral peptide element
(P2A). The retroviral vectors were used to transduce the
TCR-deficient cell line J76/CD8 and primary human PBL.
On both cell types, all three TCR were efficiently expressed
(Figs. 2a and 2b). However, substantial differences in the
capacity to bind NY-multimers were detected. On J76/CD8
cells the mean fluorescence intensity (MFI) of multimer
staining was two times higher for TCR-CM26 (MFI: 317)
and more than five times higher for TCR-ThP2 (MFI: 821)
compared to TCR-HL2 (MFI: 160) which showed the lowest
multimer binding (Fig. 2a). These differences were not due
to an unequal TCR expression as the levels of CD3 were
comparable for all TCR. None of the J76/CD8 cell lines
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bound HLA-A2 control multimers (Supporting Information
Fig. 1). On PBL, the same hierarchy concerning multimer
binding was observed. TCR-HL2-tg T cells showed the lowest
multimer binding on CD8þ cells and there was no multimer
binding by CD8 cells (Fig. 2b). For TCR-CM26 and TCR-
ThP2 multimer binding on CD8þ and CD8 cells was
observed with higher levels for TCR-ThP2 on both cell types.
These results suggested that TCR-ThP2 had a higher affinity
compared to TCR-HL2 and TCR-CM26 and should therefore
result in T cells with an increased functionality. To test this,
the cytotoxic capacity of TCR-tg T cells against T2 cells
loaded with titrated amounts of NY-ESO-1157-165 was ana-
lyzed. However, in contrast to the data obtained for multimer
binding, TCR-ThP2-tg cells showed the lowest functional
avidity as only high peptide concentrations were recognized.
TCR-HL2-tg and TCR-CM26-tg T cells revealed a more than
100-fold higher functional avidity compared to TCR-ThP2-tg
cells (Fig. 2c). The discrepancy between efficient multimer
binding and cell lysis implies that the prediction of TCR
quality based only on multimer binding is not sufficient.
Recognition of antigen-expressing tumor cells is restricted
to NY-ESO-1 TCR with moderate levels of multimer binding
To analyze whether TCR-tg T cells were able to recognize
cells presenting endogenously processed antigen, we co-cul-
tured them with different melanoma cell lines and analyzed
the concentrations of released IFN-c. TCR-ThP2-tg T cells
did not recognize any of the melanoma cell lines independent
Figure 1. Auto- and allo-HLA-A2-restricted NY-ESO-1-reactive CTL clones differ in their functionality. T cells from HLA-A2þ and HLA-A2
donors were stimulated with autologous and allogeneic HLA-A2þ NY-ESO-1157-165-loaded DC, respectively, and T cell clones were generated
by limiting dilutions. (a) Isolated clones were stained with anti-CD8 mAb and NY-multimers and analyzed by flow cytometry. (b) Cytolytic
activity against T2 cells loaded with different concentrations of NY-ESO-1157-165 was measured. The specific lysis at 1 lM was set as 100%.
(c) Cytolytic activity against NY-ESO-1 SK-Mel-29-VC and NY-ESO-1þ SK-Mel-29-NY and SK-Mel-37 melanoma cell lines was measured at
different E:T.
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Figure 2. No correlation between the level of multimer binding and the functionality of TCR-modified T cells. (a) CD8aþ Jurkat 76 cells (J76/
CD8) were transduced with optimized versions (minimally murinized, additional disulfide bond, codon-optimized) of NY-ESO-1157-165-
reactive TCR-ThP2, TCR-HL2 and TCR-CM26. Four days after transduction, cells were stained with anti-CD3 mAb and NY-multimers and
analyzed by flow cytometry. Numbers indicate the MFI of multimer staining for CD3þ/multimerþ cells. Untransduced cells were used as a
control (ut). (b) PBL from a healthy donor were transduced using the same viral supernatants as for J76/CD8 cells. Thirteen days after
isolation, cells were stained with anti-CD8 mAb and NY-multimers and analyzed by flow cytometry. MFI of multimer staining for CD8þ/
multimerþ cells and CD8/multimerþ cells are indicated. (c) Fifteen days after isolation, cytolytic activity against NY-ESO-1157-165-loaded T2
cells was measured at an E:T of 80:1. The specific lysis at 1 lM was set as 100%. (d) Transduced T cells were co-cultured with different
melanoma cell lines and concentrations of released IFN-c were analyzed by ELISA. Expression of NY-ESO-1 protein (NY) and HLA-A2 (A2) are
indicated. (e) Cytolytic activity against melanoma cell lines was measured at different E:T.
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of HLA-A2 and NY-ESO-1 expression (Fig. 2d). To exclude
that these cells were intrinsically not able to produce IFN-c,
TCR-ThP2-tg T cells were stimulated unspecifically (PMA/Ion-
omycin) and with NY-ESO-1157-165-loaded T2 cells, respec-
tively. After both types of stimulation, IFN-c was released
(data not shown). T cells transduced with TCR-HL2 and
TCR-CM26 released up to 5.2 and 6.9 ng/ml IFN-c, respec-
tively, when they were co-cultured with HLA-A2þ/NY-ESO-
1þ melanoma cell lines. Cell lines with high HLA-A2 levels
(Mel-285) or cells overexpressing NY-ESO-1 (SK-Mel-29-NY)
(Supporting Information Fig. 2) were recognized most
efficiently. No or little amount of IFN-c was released after co-
cultivation with HLA-A2 (MUC-Mel-1) or NY-ESO-1
(SK-Mel-29-VC, Me-324) melanoma cell lines. When
HLA-A2þ/NY-ESO-1 cell lines were exogenously loaded with
NY-ESO-1157-165 all TCR-tg T cells recognized these cells (data
not shown). To further characterize the TCR-tg T cells, we
tested their cytotoxic activity against different melanoma cell
lines. As before, TCR-ThP2-tg T cells were not able to recog-
nize antigen-positive melanoma cells. Only TCR-HL2-tg and
TCR-CM26-tg T cells lysed HLA-A2þ/NY-ESO-1þ cell lines
(SK-Mel-29-NY, Mel-285) (Fig. 2e).
Examining the recognition of melanoma cells lines by
TCR-transduced T cells confirmed the results from the pep-
tide titration assay. The TCR with best multimer binding but
lowest functional avidity (TCR-ThP2) showed no recognition
of endogenously processed antigen.
A NY-ESO-1 TCR of allogeneic origin shows off-target
reactivity
As TCR-ThP2-tg T cells did not recognize endogenously
processed antigen, we continued only with TCR-HL2 and
TCR-CM26. To further analyze the specificity of these two
TCR, we used a peptide library consisting of 125 peptides
known to bind to HLA-A2. The peptides were loaded on T2
cells which were then used for co-cultivation with TCR-tg T
cells. For TCR-HL2-tg T cells the concentration of released
IFN-c was at the detection limit for all peptides, except for
the NY-ESO-1157-165 positive control (Fig. 3a), indicating that
the TCR specifically recognized only the desired peptide. In
contrast, TCR-CM26-tg T cells showed increased recognition
for all peptides with a mean IFN-c release of 375 pg/ml.
Although the amount of released IFN-c was more than 25
times lower than after stimulation with the specific peptide,
the TCR-CM26-tg cells seemed to react against the HLA-
A2þ T2 cells independent of the bound peptide (Fig. 3a). To
further specify the recognition of HLA-A2 by TCR-CM26-tg
T cells, we co-cultured these cells with the NY-ESO-1/HLA-
A2 renal cell carcinoma cell line KT-195, which had been
transduced either with an HLA-A2 encoding vector or a con-
trol vector. While TCR-HL2-tg T cells did not react against
KT-195 cells (Fig. 3b), TCR-CM26-tg T cells released IFN-c
when they were co-cultivated with HLA-A2-expressing KT-
195 cells (668 pg/ml). Compared to the background seen
with NY-ESO-1/HLA-A2þ melanoma cell lines SK-Mel-
29-VC (196 pg/ml) and Me-324 (115 pg/ml) (Fig. 2d), the
concentration of released IFN-c was higher for KT-195-A2
cells, probably due to the overexpression of HLA-A2 on these
cells. The recognition of KT-195-A2 cells confirmed that
TCR-CM26 had an increased recognition of HLA-A2. The
CM26 CTL clone was derived from an allogeneic approach,
where a T cell population was used which had not been
selected against HLA-A2 in the thymus.
Discussion
We have isolated CTL clones reactive against the cancer-testis
antigen NY-ESO-1, which is a promising target antigen for
immunotherapies using TCR gene-modified T cells in cancer
patients,7 and analyzed their TCR for a potential clinical
application. For the generation of NY-ESO-1-specific clones,
we used different protocols of stimulation: autologous T cells
were stimulated with HLA-A2þ DC, which were loaded with
two different amounts of NY-ESO-1-peptide (NY-ESO-1157-
165). In a further approach, HLA-A2
 T cells were stimulated
with allogeneic HLA-A2þ DC offering the advantage that the
T cell pool had not been selected against HLA-A2/NY-ESO-1
in the thymus.
The CTL clones were compared based on their ability to
bind specific MHC-multimers and to react against peptide-
loaded T2 cells and tumor cell lines. These experiments
resulted in first hints about the quality of the TCR that were
expressed by the clones. However, a direct comparison of the
Figure 3. Peptide-independent HLA-A2 recognition by the
allogeneicly generated TCR. (a) PBL from a healthy donor were
transduced with optimized versions of NY-ESO-1157-165-reactive
TCR-HL2 and TCR-CM26. Fifteen days after isolation, TCR-tg T cells
were co-cultured with an array of T2 cells pulsed with 125 different
HLA-A2-binding peptides, including NY-ESO-1157-165 (squares), or
with unpulsed T2 cells (stars). Concentrations of released IFN-c
were determined by ELISA. (b) Transduced PBL were co-cultured
with the HLA-A2/NY-ESO-1 renal cell carcinoma line KT-195
transduced with control vector (VC) or HLA-A2-containing vector
(A2). Concentrations of released IFN-c were analyzed by ELISA.
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TCR was difficult, as the clones might have different cell-
intrinsic properties and might also vary in their capability to
grow and lyse in vitro. For a more meaningful comparison of
the different TCR, we isolated their genes and expressed
them in parallel as transgenes in primary human T cells
derived from the same donor. As evaluation criteria we used
preconditions which a TCR has to fulfill in a clinical applica-
tion: (i) efficient expression on TCR-tg T cells, (ii) recogni-
tion of its antigen with a sufficiently high affinity, so that
also endogenously processed antigen can be detected, (iii)
specificity, so that cells which do not express the targeted
antigen are not recognized (no off-target side effects).
The three analyzed TCR were efficiently expressed on
TCR-tg T cells when optimized versions (second disulfide
bond, minimally murinized and codon-optimized) of the
TCR were used. The expression of non-optimized TCR was
low for TCR-HL2 and TCR-CM26, indicating that these TCR
were weak in terms of cell surface expression.27 The specific-
ity and affinity toward the antigenic peptide was first ana-
lyzed by multimer binding assays. On all examined cell types,
multimer binding was highest for TCR-ThP2, which in addi-
tion showed efficient multimer binding on CD8 cells. While
the half maximum cytotoxicity of T cell clones ThP2 and
HL2 was very similar it differed for TCR-tg T cells by
approximately two logs (ThP2: 2  107 M, HL2: 2  109
M). According to this, TCR-ThP2 had the lowest activity in
functional assays since only high concentrations of peptide
were recognized and TCR-ThP2-tg T cells did not react
against any NY-ESO-1þ cell line. We hypothesize that there
is a threshold affinity level, which determines whether or not
a TCR recognizes endogenously presented antigen. As these
results indicated that the enhanced multimer binding of
TCR-ThP2 was not associated with improved T cell function,
it is not sufficient to assess TCR quality based on a single pa-
rameter. Similar findings were also reported for other TCR.28
The specificity of the TCR was first evaluated by screening
a small panel of NY-ESO-1/HLA-A2-expressing and non-
expressing tumor cell lines. TCR-HL2- and TCR-CM26-tg T
cells secreted high amounts of IFN-c and showed cytotoxic
activity only after co-cultivation with NY-ESO-1þ/HLA-A2þ
cells. IFN-c release and the killing capacity of TCR-CM26-tg
T cells was slightly enhanced in comparison to TCR-HL2-tg
T cells and we recognized that TCR-CM26-tg T cells secreted
small amounts of IFN-c also in the absence of NY-ESO-1-
antigen. To further evaluate the specificity of TCR-HL2 and
TCR-CM26, we screened a library consisting of 125 of com-
monly presented HLA-A2-binding peptides. Although the
number of peptides in this library is limited compared to the
overall number of HLA-A2-presented peptides on human
cells, one can assume that TCR with a broad range of peptide
recognition and TCR recognizing an HLA molecule inde-
pendent of the bound peptide can be identified. Indeed, we
found background recognition of NY-ESO-1/HLA-A2þ cells
by TCR-CM26, which was allusively seen when IFN-c release
was analyzed, but was not observed in cytotoxicity assays.
We hypothesize that the affinity of TCR-CM26 to HLA-A2
was too low to result in the killing of target cells when they
did not express NY-ESO-1. In further experiments, we got
strong indications that the recognition of NY-ESO-1/HLA-
A2þ cells by TCR-CM26 was due to HLA-A2 alloreactivity.
However, we cannot entirely exclude that one or few endoge-
nous peptides presented on T2, KT-195, SK-Mel-29 or Me-
324 cells were recognized. But, if endogenous peptides were
recognized, the reactivity against unloaded T2 cells should
have been stronger compared to peptide-loaded T2 cells,
where the endogenous peptides were replaced by the added
peptides. For a clinical application it is difficult to predict,
whether or not this background recognition of HLA-A2
would cause side effects. Off-target reactivity of TCR, which
are generated in an allogeneic priming approach of T cells is
not new and was recently described for a large number of
WT-1-specific TCR generated in such a setting.10 To circum-
vent this problem, numerous T cell clones must be estab-
lished for the identification of TCR free of alloreactivity.8
In summary, we have molecularly cloned three TCR with
specificity for the NY-ESO-1157-165 antigenic peptide derived
from different approaches of T cell priming. We showed that
an extensive evaluation using a combination of different
methods is needed to identify a candidate TCR for clinical
application. TCR-HL2, which showed an intermediate per-
formance in all functional assays, remains the only candidate
for TCR gene therapy. This TCR will now be analyzed in
preclinical mouse models.
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